3billion (CEO Changwon Geum) has been selected as the official Asian diagnostic partner for the 'iHope' program operated by the Genetic Alliance, a global rare disease patient group.
iHope, which began as an Illumina social contribution project and is now an international precision medicine support project operated by Genetic Alliance, provides whole-genome sequencing (WGS) to pediatric patients with rare diseases in regions with insufficient medical infrastructure, supporting diagnostic accessibility and treatment direction establishment.
3billion leverages its accumulated genetic diagnostic service experience in over 75 countries and AI-based mutation interpretation technology to provide a reliable WGS-based diagnostic system for pediatric rare disease patients in developing countries. According to an iHope study, using WGS as a primary diagnostic tool in low-income countries resulted in a diagnosis rate of over 60% for rare diseases, and treatment or management strategies were modified in over 70% of confirmed cases.
Sharon Terry, CEO of Genetic Alliance, said, "To end the diagnostic journey for children with rare diseases, we need a partner with both technological maturity and global reach. The addition of 3billion as our official Asian partner strengthens the iHope diagnostic network." Geum Chang-won, CEO, stated, "We will provide AI genetic diagnostic services to patients in the blind spot of precision medicine, guiding them on optimal treatment paths and contributing to the advancement of global public health."
Meanwhile, the use of AI-based genetic diagnosis services is expanding in the global rare disease diagnosis and precision medicine markets.
- See more related articles
You must be logged in to post a comment.